Clinical Trial Detail

NCT ID NCT01940172
Title Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements No
Sponsors TetraLogic Pharmaceuticals
Indications

fallopian tube cancer

peritoneum cancer

ovarian carcinoma

Therapies

Conatumumab

Birinapant

Age Groups: adult

No variant requirements are available.